Pulmatrix Inc (PULM)

[riskon]

iSPERSE is King, Multi+billion dollar company in the making, imo. ??

Pulmatrix 3 Current Pipeline Items :
1) PUR1800 (AECOPD): $2.4B Peak U.S. Rev, JNJ, Kinase Inhibitors + New Indications (IPF, Lung Cancer)
**P1B Results being prepared for data publication on chronic dosing indications - *potential near-term catalyst events*

2) PUR1900 (ABPA): Pulmazole - $1.5B Peak Rev in U.S., 50/50 CIPLA Partnership, Expansion opportunity globally & across indications, 'become new standard of care' through reducing limiting side effects on increased oral Itraconazole usage.
*P2B Starting in '23, FDA Fast Tracked, FDA Type-C Reviewed

3) PUR3100 (Migraine):
$575M
U.S. Market; Applying iSPERSE onto previous
$1B
allergen purchase of MAP004 (failed for safety)
*P1 Trials completing around now; P2 & P3 planned for 2023

And the bonus of royalty streams from FEND (PUR003/006) creating the 'air hygiene' category.

Pipeline can expand quickly with iSPERSE being applied to already in-use/developed standards of care of novelty formulations, yielding improved patient care.

$PULM